EAST HANOVER, N.J., May 24, 2019 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib, formerly BYL719) in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-), PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after an endocrine-based regimen1.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/8524851-novartis-piqray-fda-approval-breast-cancer-treatment/

PIK3CA is the most commonly mutated gene in HR+/HER2- breast cancer; approximately 40% of patients living with HR+/HER2- breast cancer have this mutation8,10. PIK3CA mutations are associated with tumor growth, resistance to endocrine treatment and a poor overall prognosis11,12. Piqray targets the effect of PIK3CA mutations and may help overcome endocrine resistance in HR+ advanced breast cancer.

"The FDA approval of Piqray, which was discovered at the Novartis Institutes for BioMedical Research, marks the first ever treatment specifically for HR+/HER2- advanced breast cancer with a PIK3CA mutation. We are proud to offer a new treatment option that specifically addresses the needs of the patients living with this mutation," said Susanne Schaffert, PhD, CEO, Novartis Oncology. "We are grateful to our researchers' bold and unrelenting pursuit of a first-in-class treatment for this incurable disease, and to the patients, investigators and administrators who participated in the clinical trials leading to this remarkable milestone."

FDA approval is based on results of the Phase III trial, SOLAR-1, that showed Piqray plus fulvestrant nearly doubled median progression-free survival (PFS) compared to fulvestrant alone in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation (median PFS 11.0 months vs 5.7 months; HR=0.65, 95% CI: 0.50-0.85; p<0.001)2. Piqray provided consistent PFS results across pre-specified subgroups, including among patients previously treated with a CDK4/6 inhibitor2,3.

Overall response rate (ORR), an indicator of the proportion of patients who experience at least a 30% reduction in overall tumor size (in patients with measurable disease), was more than doubled when Piqray was added to fulvestrant in patients with a PIK3CA mutation, (ORR= 35.7% vs 16.2% for fulvestrant alone, p=0.0002)2,3. Piqray and its associated companion diagnostic test from QIAGEN N.V. was the first combination product approved under the FDA Oncology Center of Excellence Real-Time Oncology Review pilot program. 

"Today's approval is expected to change the way we practice medicine in advanced breast cancer. For the first time, physicians can test for PIK3CA biomarkers and develop a treatment plan based on the genomic profile of a patient's cancer," said Fabrice André, MD, PhD, research director and head of INSERM Unit U981, professor in the Department of Medical Oncology at Institut Gustave Roussy in Villejuif, France, and global SOLAR-1 principal investigator. "In the SOLAR-1 Phase III trial, alpelisib plus fulvestrant nearly doubled median PFS and more than doubled overall response rate in patients with a PIK3CA mutation, offering them new hope for longer life without progression."

Patients with HR+/HER2- advanced breast cancer can be selected for treatment with Piqray based on the presence of PIK3CA mutations. Concurrent with the approval of Piqray, the therascreen®* PIK3CA companion diagnostic test from QIAGEN was also approved by the FDA and is now available for patient testing.       

"If you are facing a complex disease like metastatic breast cancer, you want to follow a path that is specific to your type of disease," said Shirley Mertz, President, Metastatic Breast Cancer Network. "Finding the right treatment team and getting the right tests, like testing for the PIK3CA mutation, will help your healthcare team identify accurate, precise treatment options for your disease."

Novartis is committed to providing patients with access to medicines, as well as resources and support to address a range of needs. The Novartis Oncology Patient Support Program is available to help guide eligible patients through the various aspects of getting started on treatment, from providing educational information to helping them understand their insurance coverage and identify potential financial assistance options. For more information, patients and healthcare professionals can call 1-800-282-7630.

Full prescribing information for Piqray can be found at https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf.

About Piqray® (alpelisib)
Piqray is a kinase inhibitor approved in combination with fulvestrant for the treatment of postmenopausal women, and men, with HR+/HER2-, PIK3CA-mutated, advanced or metastatic breast cancer, as detected by an FDA-approved test following progression on or after endocrine-based regimen1.

Approximately 40% of HR+ advanced breast cancer patients have a mutation that may activate the PI3K-alpha isoform, called PIK3CA mutations5,6,7,8. These mutations are associated with resistance to endocrine therapy, disease progression and a poor prognosis11,12. Piqray works by inhibiting the PI3K pathway, predominantly the PI3K-alpha isoform, to address the effect of PIK3CA mutations.

About SOLAR-1
SOLAR-1 is a global, Phase III randomized, double-blind, placebo-controlled trial studying Piqray in combination with fulvestrant for postmenopausal women, and men, with PIK3CA-mutated HR+/HER2- advanced or metastatic breast cancer that progressed on or following aromatase inhibitor treatment with or without a CDK4/6 inhibitor1,2,3. SOLAR-1 is the pivotal Phase III trial that supported this approval.

The trial randomized 572 patients. Patients were allocated based on central tumor tissue assessment to either a PIK3CA-mutated cohort (n=341) or a PIK3CA non-mutated cohort (n=231). Within each cohort, patients were randomized in a 1:1 ratio to receive continuous oral treatment with Piqray (300 mg once daily) plus fulvestrant (500 mg every 28 days + Cycle 1 Day 15) or placebo plus fulvestrant. Stratification was based on visceral metastases and prior CDK4/6 inhibitor treatment1,2,3. Patients and investigators are blinded to PIK3CA mutation status and treatment.

The primary endpoint is local investigator assessed PFS using RECIST 1.1 for patients with a PIK3CA mutation. The key secondary endpoint is overall survival, and additional secondary endpoints include, but are not limited to, overall response rate, clinical benefit rate, health-related quality of life, efficacy in PIK3CA non-mutated cohort, safety and tolerability1,2,3. SOLAR-1 is ongoing to assess overall survival and other secondary endpoints.

About Novartis in Advanced Breast Cancer
For more than 30 years, Novartis has been tackling breast cancer with superior science, great collaboration and a passion for transforming patient care. With one of the most diverse breast cancer pipelines and one of the largest numbers of breast cancer compounds in development, Novartis leads the industry in discovery of new therapies and combinations, especially in HR+ advanced breast cancer, the most common form of the disease.

Indication
PIQRAY® (alpelisib) tablets is a prescription medicine used in combination with the medicine fulvestrant to treat women who have gone through menopause and men who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer or breast cancer that has spread to other parts of the body (metastatic), with an abnormal phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) gene, and whose disease has progressed on or after endocrine therapy. Your health care provider will test your cancer for an abnormal "PIK3CA" gene to make sure that PIQRAY is right for you. It is not known if PIQRAY is safe and effective in children. 

Important Safety Information
Patients should not take PIQRAY if they have had a severe allergic reaction to PIQRAY or are allergic to any of the ingredients in PIQRAY. 

PIQRAY may cause serious side effects. PIQRAY can cause severe allergic reactions. Patients should tell their health care provider or get medical help right away if they have trouble breathing, flushing, rash, fever, or fast heart rate during treatment with PIQRAY. PIQRAY can cause severe skin reactions. Patients should tell their health care provider or get medical help right away if they get severe rash or rash that keeps getting worse, reddened skin, flu-like symptoms, blistering of the lips, eyes or mouth, blisters on the skin or skin peeling, with or without fever. PIQRAY can cause high blood sugar levels (hyperglycemia). Hyperglycemia is common with PIQRAY and can be severe. Health care providers will monitor patients' blood sugar levels before they start and during treatment with PIQRAY. Health care providers may monitor patients' blood sugar levels more often if they have a history of Type 2 diabetes. Patients should tell their health care provider right away if they develop symptoms of hyperglycemia, including excessive thirst, dry mouth, urinate more often than usual or have a higher amount of urine than normal, or increased appetite with weight loss. PIQRAY can cause lung problems (pneumonitis). Patients should tell their health care provider right away if they develop new or worsening symptoms of lung problems, including shortness of breath or trouble breathing, cough, or chest pain. Diarrhea is common with PIQRAY and can be severe. Severe diarrhea can lead to the loss of too much body water (dehydration) and kidney problems. Patients who develop diarrhea during treatment with PIQRAY should tell their health care provider right away. 

Before taking PIQRAY, patients should tell their health care provider if they have a history of diabetes, skin rash, redness of skin, blistering of the lips, eyes or mouth, or skin peeling, are pregnant, or plan to become pregnant as PIQRAY can harm their unborn baby. Females who are able to become pregnant should use effective birth control during treatment with PIQRAY and for 1 week after the last dose. Do not breastfeed during treatment with PIQRAY and for 1 week after the last dose. Males with female partners who are able to become pregnant should use condoms and effective birth control during treatment with PIQRAY and for 1 week after the last dose. Patients should also read the Full Prescribing Information of fulvestrant for important pregnancy, contraception, infertility, and lactation information.

Patients should tell their health care provider all of the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. PIQRAY and other medicines may affect each other causing side effects. Know the medicines you take. Keep a list of them to show your health care provider or pharmacist when you get a new medicine.

The most common side effects of PIQRAY when used with fulvestrant are rash, nausea, tiredness and weakness, decreased appetite, mouth sores, vomiting, weight loss, hair loss, and changes in certain blood tests.

Please see full Prescribing Information for Piqray, available at
https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/piqray.pdf.

Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis
Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 750 million people globally, and we are finding innovative ways to expand access to our latest treatments. About 105,000 people of more than 140 nationalities work at Novartis around the world. Novartis Pharmaceuticals Corporation, a US affiliate of Novartis, is located in East Hanover, NJ. Find out more at www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact This email address is being protected from spambots. You need JavaScript enabled to view it.

References

  1. Piqray (alpelisib) Prescribing Information. East Hanover., New Jersey, USA: Novartis Pharmaceuticals Corporation; May 2019.
  2. André F, Ciruelos E, Rubovszky G. Alpelisib for PIK3CA-Mutated, Hormone-Receptor-Positive Advanced Breast Cancer. N Eng J Med 2019.
  3. André F, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Annals of Oncology, Vol 29, Suppl 8, October 2018, Abstract LBA3_PR.
  4. Juric D, Ciruelos EM, Rubovszky G et al. Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Phase 3 SOLAR-1 trial results. Presented at the San Antonio Breast Cancer Symposium (SABCS) (Abstract #GS3-08) on December 6, 2018.
  5. Tolaney S, Toi M, Neven P, et al. Presented at: 2019 American Association for Cancer Research (AACR) Annual Meeting; March 29-April 3, 2019; Atlanta, GA.
  6. Di Leo A, Johnston S, Seok Lee K, et al. Lancet Oncol. 2018;19(1):87-100.
  7. Moynahan ME, Chen D, He W, et al. Br J Cancer. 2017;116(6):726-730002E
  8. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
  9. Sobhani N, Roviello G, Corona SP et al. The prognostic value of PI3K mutational status in breast cancer: a meta-analysis. J Cell Biochem. 2018;119(6):4287-4292.
  10. Sabine V, Crozier C, Brookes C, et al. Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. Journal of Clinical Oncology. 2014;32:2951-2958.
  11. Miller TW, Rexer BN, Garrett JT, et al. Mutations in the Phosphatidylinositol 3-Kinase Pathway: Role in Tumor Progression and Therapeutic Implications in Breast Cancer. Breast Cancer Res. 2011.
  12. Saal LH, Johansson P, Holm K. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. PNAS. 2007;104(18):7564-7569.

*therascreen is a registered trademark of QIAGEN N.V.

SOURCE Novartis Pharmaceuticals Corporation

Read more: FDA approves Novartis Piqray® - the first and...

SILVER SPRING, Md., May 24, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.

The FDA also approved the companion diagnostic test, therascreen PIK3CA RGQ PCR Kit, to detect the PIK3CA mutation in a tissue and/or a liquid biopsy. Patients who are negative by the therascreen test using the liquid biopsy should undergo tumor biopsy for PIK3CA mutation testing.

"Piqray is the first PI3K inhibitor to demonstrate a clinically meaningful benefit in treating patients with this type of breast cancer. The ability to target treatment to a patient's specific genetic mutation or biomarker is becoming increasingly common in cancer treatment, and companion diagnostic tests assist oncologists in selecting patients who may benefit from these targeted treatments," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. "For this approval, we employed some of our newer regulatory tools to streamline reviews without compromising the quality of our assessment. This drug is the first novel drug approved under the Real-Time Oncology Review pilot program. We also used the updated Assessment Aid, a multidisciplinary review template that helps focus our written review on critical thinking and consistency and reduces time spent on administrative tasks."

Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body (most often the bones, lungs, liver or brain). When breast cancer is hormone-receptor positive, patients may be treated with anti-hormonal treatment (also called endocrine therapy), alone or in combination with other medicines, or chemotherapy.

The efficacy of Piqray was studied in the SOLAR-1 trial, a randomized trial of 572 postmenopausal women and men with HR-positive, HER2-negative, advanced or metastatic breast cancer whose cancer had progressed while on or after receiving an aromatase inhibitor. Results from the trial showed the addition of Piqray to fulvestrant significantly prolonged progression- free survival (median of 11 months vs. 5.7 months) in patients whose tumors had a PIK3CA mutation.

Common side effects of Piqray are high blood sugar levels, increase in creatinine, diarrhea, rash, decrease in lymphocyte count in the blood, elevated liver enzymes, nausea, fatigue, low red blood cell count, increase in lipase (enzymes released by the pancreas), decreased appetite, stomatitis, vomiting, weight loss, low calcium levels, aPTT prolonged (blood clotting taking longer to occur than it should), and hair loss.  

Health care professionals are advised to monitor patients taking Piqray for severe hypersensitivity reactions (intolerance). Patients are warned of potentially severe skin reactions (rashes that may result in peeling and blistering of skin or mucous membranes like the lips and gums). Health care professionals are advised not to initiate treatment in patients with a history of severe skin reactions such as Stevens-Johnson Syndrome, erythema multiforme, or toxic epidermal necrolysis. Patients on Piqray have reported severe hyperglycemia (high blood sugar), and the safety of Piqray in patients with Type 1 or uncontrolled Type 2 diabetes has not been established. Before initiating treatment with Piqray, health care professionals are advised to check fasting glucose and HbA1c, and to optimize glycemic control. Patients should be monitored for pneumonitis/interstitial lung disease (inflammation of lung tissue) and diarrhea during treatment. Piqray must be dispensed with a patient Medication Guide that describes important information about the drug's uses and risks.

Piqray is the first new drug application (NDA) for a new molecular entity approved under the Real-Time Oncology Review (RTOR) pilot program, which permits the FDA to begin analyzing key efficacy and safety datasets prior to the official submission of an application, allowing the review team to begin their review and communicate with the applicant earlier. Piqray also used the updated Assessment Aid (AAid), a multidisciplinary review template intended to focus the FDA's written review on critical thinking and consistency and reduce time spent on administrative tasks. With these two pilot programs, today's approval of Piqray comes approximately three months ahead of the Prescription Drug User Fee Act (PDUFA) VI deadline of August 18, 2019.

The FDA granted this application Priority Review designation. The FDA granted approval of Piqray to Novartis. The FDA granted approval of the therascreen PIK3CA RGQ PCR Kit to QIAGEN Manchester, Ltd.

For more information:

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Amanda Turney, 301-796-2969, This email address is being protected from spambots. You need JavaScript enabled to view it. 
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

Related Links

http://www.fda.gov

Read more: FDA approves first PI3K inhibitor for breast...

HAUPPAUGE, N.Y., May 24, 2019 /PRNewswire/ -- There is nothing more memorable than your first summer as a pool owner. You have spent months, or even years, of planning and now the time has finally arrived to enjoy numerous lazy summer days by the pool. However, pool season is quick and fleeting in the grand scheme of the calendar year. Inground pool liners manufacturer, LOOP-LOC, discusses how new pool owners can make the most out of their first swimming pool season.

  • Plan poolside events. What better way to celebrate your newly open pool than with a party? Answer: there is none! Pools were meant for swimmers and parties bring swimmers, which is why the summer season is the best time to plan events for family and friends to enjoy your new backyard oasis. However, poolside events don't always mean parties, a poolside dinner with the immediate family is a great alternative to a party when looking for a low-key evening.
  • Extend your pool season. If you and your family can't get enough of pool season, try extending it. There are numerous options to help extend your pool season, whether that means opening your pool earlier or closing it later. However, if you decide to go that route think about investing in a pool heater. The warmer water will be a much-needed addition when trying to swim when the air is cooler. Either a gas heater or heat pump can help keep your pool water warm and inviting when the air begins to change.
  • Keep your pool clean. Pool season is already a limited-time engagement, no need to shorten the season with water chemical imbalances. For first-time pool owners, you'll want to remember to have your pool water tested constantly. Either professionally or at home, testing the chemical levels in your pool is imperative to a successful pool season. Remember, keeping the pool clean isn't just about the chemicals in your water, it is also about the filter. Don't forget to constantly check your filter and clean or replace cartridges when needed. A clean filter will help to keep clean water circulating throughout.

Pool season is fleeting, be sure to enjoy every moment of your first season as pool owner with these tips.

ABOUT LOOP-LOC: There's only one company known for manufacturing safety pool covers strong and tough enough to support an elephant: the legendary LOOP-LOC. LOOP-LOC is a global leader in the pool industry with a 200,000-square-foot headquarters in Hauppauge, New York, and 300 employees. Through its network of dealers, the company has sold safety swimming pool covers on every continent on Earth except Antarctica. LOOP-LOC now also manufactures a line of luxury in-ground pool liners—with more exclusive designer patterns than any other company—as well as the BABY-LOC removable fencing, a convenient, cost-effective additional layer of protection to help deter toddlers from gaining access to a swimming pool.

SOURCE LOOP-LOC

Related Links

https://www.looploc.com

Read more: Inground Pool Liners Manufacturer, LOOP-LOC,...

Many enhancements were made to the building to improve tenant satisfaction and retention, increase leasing activity, and reduce operational expenses.  Improvements included unit interior renovations, new hot water boiler, solar thermal system, exterior paint, landscaping, new roof, renovated elevator cab, new intercom and access control system.

"After the successful sale of our nearby building at 3960 W. 8th Street, we are continuing that momentum with the sale of 2933 W. 8th Street," said Kamyar Shabani, a principal of Optimus Properties, LLC. "The disposition of these assets provide more resources for new acquisitions, such as our recent purchase of a 35,449 sq. ft. office building at 19725 Sherman Way in Winnetka, CA, a 60,804 sq. ft. office building at 2325 Crenshaw Boulevard in Torrance, and a soon to be announced acquisition of an 85,000 sq. ft. medical office building."

"This building will be exchanged into a larger asset that fits our current company strategy," said K. Joseph Shabani, a principal of Optimus Properties, LLC.

Optimus Properties, LLC, located in Los Angeles, California, was founded by Kamyar Shabani and K. Joseph Shabani and employs a disciplined investment approach focused on value creation in multifamily properties throughout Los Angeles.

SOURCE Optimus Properties, LLC

Read more: Optimus Properties, LLC Sells 40 Unit Apartment...

DUBLIN, May 24, 2019 /PRNewswire/ -- The "Low Voltage DC Circuit Breaker Market by End User (Battery Systems, Transportation, and Others), Application (Industrial, Commercial, and Others), Type (Air Circuit Breaker, Molded Case Circuit Breaker, and Others), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The global low voltage DC circuit breaker market is projected to reach USD 1.5 billion by 2024 from an estimated USD 1.2 billion in 2019, at a CAGR of 5.68 %.

This growth can be attributed to factors such as expansion in transmission & distribution networks and upgradation & modernization of aging infrastructure for safe and secure electrical distribution systems along with the increased emphasis on the generation of electrical energy by means of renewables such as solar. However, risks associated with device malfunction and lack of existing government policies specific to low voltage DC circuit breakers are hindering the growth of the low voltage DC circuit breaker market.

The others segment is expected to be the fastest growing market from 2019 to 2024.

The others segment, by application, is estimated to be the largest as well as the fastest growing segment during the forecast period, as the dependence on electronic equipment in the residential sector has been increasing very fast that require low voltage Direct Current (DC) for their operations. With most of the existing electrical infrastructure expected to undergo a massive revamp in the near future, for instance, electricity distribution infrastructure in the US is believed to be from the world war 2 era, thus needs to be revamped. Also, in the Asia Pacific in order to incorporate the electricity generated from renewable energy sources the infrastructure needs to be revamped. All this will ensure that the low voltage dc circuit breaker installations go up.

The battery systems segment, by end-user, is expected to be the largest market from 2019 to 2024.

The battery systems segment is expected to hold the largest market share and is expected to be the fastest growing segment during the forecast period because of large scale energy storage projects coming up in the future, globally. This is bound to be supported by the ever-increasing electricity generation from renewable energy sources because of the ever-rising demand for power throughout the world. All of this is ultimately expected to drive the market during the forecast period.

The molded case circuit breaker segment, by type, is expected to be the largest market from 2019 to 2024.

The molded case circuit breaker segment is expected to hold the largest market share during the forecast period as a vast majority of low voltage DC circuit breaker applications deploy this type of circuit breaker owing to the ease of installation, reliability of operation, and low price when compared with other options. Electricity distribution substations and industries like transportation, chemical, mining, and marine are in demand for equipment operating in the low to medium voltage segment. Hence maximum low voltage DC circuit breakers lie in this voltage rating segment.

Asia Pacific: The largest market for low voltage DC circuit breakers.

The Asia Pacific region is expected to be the largest market for low voltage DC circuit breakers, by 2024. Countries such as China, Japan, and South Korea are among the major countries which are considered as the main manufacturing hubs for low voltage DC circuit breakers. Over the past few years, this region has witnessed a high rate of economic development due to a large number of manufacturing and industrial units coming up.

Also, the growth of the electricity generation from renewable energy sources in this region results in an increase in the low voltage DC circuit breaker market. The renewable energy generation in countries like China, South Korea, Japan, and India, is taking place at a rapid rate, this needs to be incorporated in the existing national grid which would need additional electrical infrastructure, thereby driving the low voltage DC circuit breaker market.

The leading players in the low voltage DC circuit breaker market are ABB (Switzerland), Eaton (US), SIEMENS AG (Germany), Shaanxi Baoguang Vacuum Electric Device Company Limited (China), and Meidensha Corporation (China).

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increase in the Generation of Electricity From Renewable Energy Sources
5.2.1.2 Increasing Investments in Smart Grids to Ensure Grid Stability
5.2.1.3 Shift Toward Decentralized Power Generation & Energy Storage
5.2.2 Restraints
5.2.2.1 Inconsistencies Leading to Vulnerability Causing Operational Failures
5.2.2.2 Lack of Existing Government Policies Specific to Low Voltage DC Circuit Breakers
5.2.3 Opportunities
5.2.3.1 Development of Smart Cities & Electric Vehicles
5.2.3.2 Replacement of Old & Aging Electrical Infrastructure
5.2.3.3 Demand for Uninterrupted Power Supply From Utilities
5.2.4 Challenges
5.2.4.1 Expensive When Compared to Alternative Products
5.2.4.2 Concerns About the Cybersecurity of the Power Grid

6 Low Voltage DC Circuit Breaker Market, By Type
6.1 Introduction
6.2 By Type
6.2.1 Air Circuit Breaker
6.2.1.1 Finds Usage Mostly in Commercial Segments
6.2.2 Molded Case Circuit Breaker
6.2.2.1 Mostly Used in the Low Voltage Category
6.2.3 Others

7 Low Voltage DC Circuit Breaker Market, By Application
7.1 Introduction
7.2 By Application
7.2.1 Industrial
7.2.1.1 Increasing Automation is Likely to Drive the Market
7.2.2 Commercial
7.2.2.1 Growing Commercial Areas Globally Would Drive the Market
7.2.3 Others

8 Low Voltage DC Circuit Breaker Market, By End-User
8.1 Introduction
8.2 End-User
8.2.1 Battery System
8.2.1.1 Battery System Segment is Expected to Experience Huge Growth in Asia Pacific and North American Markets
8.2.2 Data Center
8.2.2.1 With Increasing Digitization, the Segment is Expected to Develop Massively
8.2.3 Solar
8.2.3.1 The Major Segment Driving the Renewables Market Ahead
8.2.4 Transportation
8.2.4.1 Charging Stations for Electric Vehicles are Expected to Have Massive Investments in North America and Europe
8.2.5 Others

9 Low Voltage DC Circuit Breaker Market, By Region

10 Competitive Landscape
10.1 Overview
10.2 Ranking of Players and Industry Concentration, 2017
10.3 Competitive Landscape Mapping, 2018
10.4 Competitive Scenario
10.4.1 Contracts & Agreements
10.4.2 Investments & Expansions
10.4.3 Mergers & Acquisitions
10.4.4 Others

11 Company Profiles
11.1 ABB
11.2 Eaton
11.3 Schneider Electric
11.4 Tavrida Electric
11.5 Hitachi
11.6 Fuji Electric
11.7 Powell Industries
11.8 Sensata Technologies
11.9 SIEMENS AG
11.10 C&S Electric
11.11 Hyundai Electric & Energy Systems Company
11.12 Mitsubishi Electric Corporation
11.13 Larsen & Toubro
11.14 Rockwell Automation
11.15 Entec Electric & Electronic

For more information about this report visit https://www.researchandmarkets.com/r/evncml

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
This email address is being protected from spambots. You need JavaScript enabled to view it.  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Read more: Global Low Voltage DC Circuit Breaker Market...

Growatt Co-founder and CEO David Ding welcomed guests at the event, "We would like to take this opportunity to thank all of our partners for your support all these years. Growatt highly values collaboration with local partners and are committed to providing better products and services. The opening of Rotterdam office is a further step in improving our customer services."

So far Growatt has become the No.2 inverter brand in the residential sector of Netherlands solar market and has become the main supplier for the iChoosr projects. After eight years of rapid growth, it's now increasing investments across Europe, establishing offices, hiring staff and launching marketing campaigns.

"We are now in a better position to expand our business activities. Like other branch offices, Rotterdam office is staffed with local Dutch speaking service engineers and we will be able to hold training sessions in the office for our customers as well," said Ramon Lee, Growatt EMEA Director. Moving forward, Growatt will deal directly with import Customs clearance and handle regulatory affairs.

"Our service will be greatly improved. We can keep and manage sufficient inventory in our warehouse and provide faster delivery of inverters or replacements. Customers can focus more on developing new projects and growing business together with us."

With such foundation, Lee is looking beyond Benelux countries. "Netherlands is the fifth country after Germany, Italy, Hungary and UK in Europe where we have established our branch offices. We will integrate our resources and build a network that will boost our sales across Europe. We have confidence in strong business growth in European region and we'll continue to increase our investments and work closely with our partners."

SOURCE Growatt

Related Links

www.growatt.com

Read more: Growatt Holds Grand Opening Ceremony for...

 

• The Azov wind farm, which is also the Rostov region’s first-ever renewable project, is expected to enter into service in 2020;
• The wind project is owned by Enel Russia, with Enel Green Power in charge of development and construction activities;
• The overall investment in this plant amounts to approx. 132 million euros.

Enel Green Power (“EGP”), the Enel Group's global business line dedicated to renewable energy, started construction today of the 90 MW Azov wind farm located in the Rostov region, Southern Russia, marking the Group’s first renewable project in Russia. The wind farm, which is also the Rostov region’s first-ever renewable facility, is owned by the Group’s subsidiary Enel Russia while EGP is in charge of construction activities after having completed the development stage. Today’s cornerstone laying ceremony for the Azov wind farm was attended by Enel Russia General Director Carlo Palasciano Villamagna, Governor of the Rostov region Vasiliy Golubev, Italian Ambassador to Russia Pasquale Terracciano and other regional authorities.

Antonio Cammisecra, Global Head of Enel Green Power, said: "With this new wind project, we are embarking upon our journey towards the creation of a renewable footprint in Russia. We are looking forward to producing energy with both our Russian wind farms, and we will continue scouting for new opportunities in this renewables-rich country. Moving ahead, we plan to further leverage on this wealth of resources and keep on fuelling Russia’s economy through an increasingly diversified generation mix.”

Enel Russia’s overall investment in the Azov wind farm amounts to approximately 132 million euros. The project is expected to enter into service by the end of 2020, and will be able to generate around 320 GWh of clean energy each year once fully operational, avoiding the annual emission of around 260,000 tonnes of CO2 into the atmosphere. The wind facility will consist of 26 turbines spread across 133 hectares.

Enel Russia was awarded the Azov wind farm, along with the 201 MW Murmansk wind farm, for a total capacity of 291 MW, in the 2017 Russian government tender for the construction of 1.9 GW of wind capacity in the country. EGP is in charge of the development and construction of both projects. Enel Russia’s overall investment in the two facilities amounts to approximately 405 million euros, with the investment on the 201 MW wind farm amounting to around 273 million euros.

Enel Russia is a power generation company, controlled by Enel, which operates four thermal power plants in the Russian Federation with a total installed capacity of around 9.5 GW.

Enel Green Power (enelgreenpower.com) is the global business line of the Enel Group dedicated to the development and operation of renewables across the world, with a presence in Europe, the Americas, Asia, Africa and Oceania. Enel Green Power is a global leader in the green energy sector with a managed capacity of more than 43 GW across a generation mix that includes wind, solar, geothermal and hydropower, and is at the forefront of integrating innovative technologies into renewable power plants.

Read more: Enel Green Power Starts Construction of 90 MW...

CHARLOTTE, N.C., May 24, 2019 /PRNewswire/ -- Piedmont Natural Gas, a subsidiary of Duke Energy (NYSE: DUK), has successfully closed a $600 million debt offering – its largest debt issuance in the history of the company and its first since it merged with Duke Energy.

This transaction, which involved three disabled-veteran-owned banks as co-underwriters to sell the notes, aligns with Duke Energy's practice of routinely involving diversity-owned financial institutions in its capital raising efforts. Over the past three years, the company has worked with firms representing various backgrounds, including women-owned, African American-owned, disabled-veteran-owned and Hispanic-owned banks.

"Our focus on diversity and inclusion is unwavering – from our employees and leadership team to our suppliers, brokerage firms and investors," said Steve Young, Duke Energy's chief financial officer. "These partnerships enable us to broaden our investor base and honor veterans while also accessing low-cost capital to invest in important infrastructure for our customers."

"We are proud to be a part of this historic transaction for Piedmont Natural Gas," stated Ron Quigley, managing director at Mischler Financial, one of the disabled-veteran-owned banks participating in the transaction. "Not only does this represent another successful collaborative effort within the business community, it also carries more meaning to our firm given the timing of Memorial Day and our commitment to donate a portion of the proceeds from this transaction to causes that are important to our veteran employees."

Piedmont priced the bonds on May 21 and closed the transaction on May 24. Net proceeds will be used to retire a bank loan, repay other borrowings and other general corporate purposes.

"Everyone benefits when we bring diverse thoughts, perspectives and talents to the table," said Young. "Together, we have an opportunity to foster more innovation, enhance outreach to customers and investors and increase the business community's commitment to collaborating with a wide variety of firms."

Duke Energy

Duke Energy (NYSE: DUK), a Fortune 150 company headquartered in Charlotte, N.C., is one of the largest energy holding companies in the U.S. It employs 30,000 people and has an electric generating capacity of 51,000 megawatts through its regulated utilities and 3,000 megawatts through its nonregulated Duke Energy Renewables unit.

Duke Energy is transforming its customers' experience, modernizing the energy grid, generating cleaner energy and expanding natural gas infrastructure to create a smarter energy future for the people and communities it serves. The Electric Utilities and Infrastructure unit's regulated utilities serve approximately 7.7 million retail electric customers in six states – North Carolina, South Carolina, Florida, Indiana, Ohio and Kentucky. The Gas Utilities and Infrastructure unit distributes natural gas to more than 1.6 million customers in five states – North Carolina, South Carolina, Tennessee, Ohio and Kentucky. The Duke Energy Renewables unit operates wind and solar generation facilities across the U.S., as well as energy storage and microgrid projects.

Duke Energy was named to Fortune's 2019 "World's Most Admired Companies" list and Forbes' 2019 "America's Best Employers" list. More information about the company is available at duke-energy.com. The Duke Energy News Center contains news releases, fact sheets, photos, videos and other materials. Duke Energy's illumination features stories about people, innovations, community topics and environmental issues. Follow Duke Energy on Twitter, LinkedIn, Instagram and Facebook.

Contact: Catherine Butler
24-Hour: 800.559.3853

SOURCE Duke Energy

Read more: Piedmont Natural Gas completes its largest debt...

NEW YORK, May 23, 2019 /PRNewswire/ -- Power Bank Market - Overview

The power bank market report provides analysis for the period 2016–2027, wherein 2019 to 2026 is the forecast period and 2018 is the base year.The report covers all the major driving factors and key trending topics impacting the growth of the power bank market over the forecast period.

Read the full report: https://www.reportlinker.com/p05775457/?utm_source=PRN

It also highlights the restraints and opportunities expected to influence the market during the aforesaid period. The study provides a comprehensive outlook on the growth of the power bank market throughout the forecast period across different geographies, including North America, Europe, Asia Pacific, Middle East & Africa (MEA), and South America.

The report covers the entire overview of the market including the market dynamics such as drivers, restraints, opportunities, and trends that are predicted to leverage the existing nature and prospective status of this market.The competitive position of the power bank market is studied through the Porter's Five Forces analysis.

Additionally, current indicators of diverse macro-economic factors are contextualized under key market indicators.

The power bank market has been analyzed in (US$ Mn) in terms of revenue, in (Million Units) in terms of volume, and the CAGR (%) for the forecast period 2019 to 2027 has been provided. The power bank market is a global report studied on the basis of product type, capacity, battery type, port type, application, charging source, distribution channel, and region.

The report also highlights the competitive landscape of the power bank market, thereby positioning all the major players according to their geographic presence and recent key developments.The comprehensive power bank market estimates are the result of our in-depth secondary research, primary interviews, and in-house expert panel reviews.

Apart from that, market share analysis has been included under the competitive landscape to understand the top players' contribution in the power bank market.Each company is studied on the basis of basic information, financial highlights, revenue highlights of regional contribution and segment contribution, and product portfolio.

Additionally, the company strategy and recent developments if any are also incorporated under each company profile section.

Some of the key players in this market include Anker Technology Co. Limited, Apacer Technologies, Inc., Braven LC – INCIPIO Technologies, Inc., EasyAcc.com, Inc., Goal Zero Corporation, GP Batteries International Ltd, IEC Technology, LLC, Maxell Holdings, Ltd., MiPow Limited, Mophie, Inc., Panasonic Corporation, RavPower, Samsung Electronics Co., Ltd., Sony Corporation, and Xtorm. The key players operating in the power bank market adopt numerous strategies to sustain in the market.

Power Bank Market

By Product Type
Portable Power Banks
Phone Charging Cases
Solar Power Banks

By Capacity
Up to 5,000 mAh
5,001 mAh – 12,000 mAh
12,001 mAh – 20,000 mAh
Above 20,000 mAh

By Battery Type
Lithium Polymer
Lithium Ion

By Port Type
Standard
Type C
DC Power Jack

By Application
Smartphone
Tablet/Laptops
PCs
Camera
Others(Bluetooth Speakers, Kindle etc.)

By Charging Source
Electric
Solar
Hybrid

By Distribution Channel
Online Distribution Channel
Offline Distribution Channel
Supermarkets & Hypermarkets
Exclusive Stores
Multiband Retail Stores
Others

By Geography
North America
U.S.
Canada
Europe
U.K.
Germany
France
Rest of Europe
Asia Pacific
China
India
Japan
Rest of Asia Pacific
Middle East & Africa (MEA)
GCC
Rest of Middle East & Africa
South America
Brazil
Rest of South America

Read the full report: https://www.reportlinker.com/p05775457/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: This email address is being protected from spambots. You need JavaScript enabled to view it.
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

http://www.reportlinker.com

Read more: Power Bank Market ; Charging Source - Global...

ATLANTA, May 23, 2019 /PRNewswire/ -- As the largest non-governmental provider of recreation facilities in the state, Georgia Power today is reminding customers and lake visitors of water safety for the start of the Memorial Day weekend. Drowning is the second leading cause of accidental death for children 1 to 4 years of age, according to the Georgia Department of Public Health and SPLASH, a longstanding Georgia Department of Natural Resources initiative supported by Georgia Power. Through public outreach, the organizations aim to greatly reduce the number of these deaths and injuries.

SPLASH encourages citizens to follow these tips when enjoying beaches, pools, lakes, rivers and other bodies of water:

  • Supervision – Designate an adult to watch children at all times. Do not assume someone else is watching.
  • Prevention – Wear personal flotation devices (PFD or life jacket), install fencing around pools, and use drain covers in pools.
  • Look before you leap – Never jump into water without knowing how deep it is and what is below the surface.
  • Arm's Length – Adults should be arm's length to children in water, and safety tools such as hooks should be nearby at all times.
  • Swim Lessons – Knowing how to swim greatly reduces the chance of drowning. Classes are often available through the Red Cross or YMCA.
  • Have a Water Safety Plan – Know what to do during an emergency.

Georgia Power provides recreational opportunities year-round for the public at more than 40 sites.  The company owns and operates 15 lake properties across Georgia for power generation and resident recreation, making it easy to find a Georgia Power lake near to you.

Find out more by visiting Georgia Power's Lakes & Recreation site. There you will find detailed information about all of the Georgia Power properties, including facilities and amenities, local attractions and water safety information. On the site, visitors can also check current lake conditions, virtually explore camp sites and browse an interactive fish guide for each of the lakes.

In addition, the company provides additional water safety tips through its lake safety public service announcement on the Georgia Power YouTube Channel.

About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.6 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy at rates below the national average, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is consistently recognized by J.D. Power and Associates as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).

SOURCE Georgia Power

Related Links

http://www.georgiapower.com

Read more: Georgia Power kicks off Memorial Day weekend...

TOKYO, May 24, 2019 /PRNewswire/ -- Daiki Axis (TOKYO: 4245) is pleased to announce its results for the three months ended March 31, 2019.

Summary of Results

The Company has formulated a new medium-term management plan, "Make FOUNDATION Plan (Promote ESG)," for the fiscal years ending December 31, 2019 to 2021. The company started off the plan by transitioning to a company with an audit and supervisory committee and introducing an executive officer system. The Company's main business strategy is to focus on ensuring future revenue and profits through several initiatives. First, in the environmental equipment segment, the Company is bolstering sales overseas and strengthening the management of its recurring-revenue energy service company (ESCO) businesses in the areas of maintenance and water utilities. Second, Daiki Axis is transitioning toward growth businesses in the household equipment-related business segment. Third, in the renewable energy segment the company is working to realize a recycling society and striving to shore up stable revenue and profits.

During the first three months of the fiscal year ending December 31, 2019, the Company generated net sales of JPY9,750 million (up 0.3% YoY), operating income of JPY470 million (up 23.1% YoY), ordinary income of JPY513 million (up 21.4% YoY) and profit attributable to owners of parent of JPY302 million (up 25.3% YoY).

In the environmental equipment segment, sales of wastewater treatment systems were up year on year. Performance in Japan was affected by the posting of sales based on the percentage-of-completion-system for recognizing revenues on large-scale projects and the completion of five projects involving the sale of equipment in the water utilities business (excluding ESCO). Overseas sales rose as the Company made progress in cultivating distributors. Sales also grew year on year in the recurring-revenue energy service company (ESCO) businesses in the areas of maintenance and water utilities. Sales in the environmental equipment segment accordingly amounted to JPY5,668 million (up 17.3% YoY), and segment income (operating income) was JPY556 million (up 33.7% YoY).

Sales and income were both down in the household equipment-related business segment. In construction-related sales, the Company saw few medium-sized or large projects, and sales of retail products through DIY stores were down due to lower sales to existing stores. Also, in the construction of residential machinery the company did not benefit from large scale store construction as it had in the preceding fiscal year. Consequently, segment sales in the household equipment-related business segment came to JPY3,523million (down 19.3% YoY), and segment income (operating income) sales were JPY89 million (down 45.5% YoY).

In the renewable energy segment, sales of electricity from solar power generation rose significantly as the Company steadily commenced electricity sales. In addition, sales of biodiesel fuel were up year on year. The Company posted no sales results for the compact wind generation business. Consequently, segment sales came to JPY114 million (up 184.5% YoY), and segment income (operating income) was JPY22 million (a segment loss [operating loss] of JPY56 million in the same period of the previous year.)

In other segments, construction sales in the engineering business were down year on year in the first quarter. Sales were essentially flat year on year in the household water drinking business. As a result, segment sales were JPY443 million (down 8.6% YoY), and segment income (operating income) was JPY30 million (down 50.9% YoY).

Daiki Axis Co., Ltd. (4245, First Section, TSE) "Summary of Consolidated Financial Results for the Three Months Ended March 31, 2019" is available here:
Summary of Consolidated Financial Results for the Three Months Ended March 31, 2019

Release Disclaimer

This release is for the purpose of providing information to serve as a reference for investment decisions and not for the purpose of soliciting investment. Please you're your own judgment on final decisions such as investment policy, timing and selection. Please be advised that we do not assume any responsibility for damages caused by this service.

Release Inquiries
Borderless IR Co., Ltd.
Sixth Floor, Toyo Building 1-2-10 Nihonbashi, Chuo-ku, Tokyo 103-0027 JAPAN
TEL: +81-3-4588-6706
info@b-ir.co.jp

Borderless IR specializes in the global distribution of IR content, including the dissemination of newsletters and annual reports providing the latest information and main strengths of Japanese companies directly to overseas investors through leading global media, corporate information database services and mailing lists. Borderless is also engaged in supporting other global IR efforts.

©Borderless IR Co., Ltd. All rights reserved
The content of this release may not be duplicated or reproduced.

SOURCE Daiki Axis Co., Ltd.

Read more: Daiki Axis Co., Ltd. (4245, First Section, Tokyo...

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Fifth paragraph, first sentence should read "...and with more demand..." (instead of "...and more and more demand..."). Fifth paragraph, fourth sentence should read "...marginal China demand is still critical..." (instead of "...marginal China is still critical...").

The corrected release reads:

6TH ANNUAL ROTH CHINA SOLAR TOUR TO BE HELD IN CONJUNCTION WITH SNEC POWER EXPO IN SHANGHAI JUNE 3-6, 2019

ROTH Investor Tour to Meet with ~20 Solar Power and Clean Technology Companies on Booth Tours and Facility Visits

ROTH Capital Partners (ROTH), www.roth.com, a full-service investment bank focused on serving emerging growth companies and their investors, today announced that it will host its 6th Annual China Solar Tour in Shanghai on June 3-6, 2019. The event is held in conjunction with SNEC – 13th Annual International Photovoltaic Power Generation and Smart Energy Exhibition & Conference, one of the largest annual solar & smart energy conferences/expos in the world.

This invitation-only event, which will be hosted by ROTH’s Cleantech Senior Research Analysts Philip Shen and Craig Irwin, will provide an opportunity for industry executives and institutional investors to meet and exchange views on the latest industry trends & issues.

“We are at the beginning of a new era of solar: Subsidy-free economic demand. We expect this to be a key theme in the current upcycle as we believe the industry has quietly reached the Holy Grail inflection point of unsubsidized demand. This will result in future solar cycles becoming increasingly more driven by the global economic cycle, rather than individual country subsidy policies. We are already starting to see subsidy-free green shoots of demand throughout the world, especially in Europe, and eventually throughout the world. Moreover, we expect the industry structure to consolidate at an accelerating pace as many companies will likely not be able to maintain the R&D investment and capex required to remain profitable and competitive. Our tour is designed to explore these trends and more to uncover investment opportunities,” said Jesse Pichel, Managing Director – Cleantech Investment Banking at ROTH.

“Additionally, this year we are touring some of the largest EV and battery module suppliers to the Chinese Electric vehicle supply chain. China is the largest producer and end market for electrical vehicles.”

According to Mr. Shen, “We expect industry visibility to improve commensurate with less and less dependence on country subsidy policies and with more demand supported by non-subsidy enabled economics. This improved visibility, in our view, will lead to multiple expansion for the overall sector over time. We believe investors do not fully appreciate this yet, but we expect this to be a theme for years to come. That said, marginal China demand is still critical to the current solar cycle. With the SNEC Power Generation and Smart Energy Expo as the largest solar and storage conferences in the world, we expect our booth tour at SNEC to provide investors with insight into how China’s growth could drive near-term supply/demand dynamics as well as how this new era of subsidy-free economic demand will sustain the industry for years to come.”

“We plan to meet with companies representing each step of the power generation and smart energy value chain, including: (1) Upstream polysilicon producers; (2) Midstream wafer, cell, and module manufacturers; (3) BOS/Inverter suppliers; (4) Equipment manufacturers; (5) Downstream players; (6) Energy Storage, Hydrogen Energy and Fuel Cell Technology Companies, and (7) Industry experts.”

Craig Irwin will be giving two speeches during the SNEC Conference and EXPO. The closing keynote on June 4th titled “Energy Storage: Emerging Paradigms in Transportation and Utility” during the sub event named 2019 Int’l Energy Storage and Hydrogen & Fuel Cell Engineering Technology Conference. On June 5th, during the 8th Global Green Energy and PV Financial Summit, Mr. Irwin will be on a panel titled “Green finance: What are the various options available and how are they supporting industry growth?”. For details on the SNEC agenda and panels, see - http://www.snec.org.cn/HomePage.aspx?lang=en.

This trip will include booth tours during the SNEC Power Generation and Smart Energy Expo, which will feature nearly 2,000 companies and exhibitors from over 90 countries, a tour of the Human Horizons manufacturing facility, and the WM Motor facility in Shanghai, as well as, a tour of Wuxi Lead Intelligent Equipment facility in Jiangsu.

Clients interested in attending should contact their ROTH sales representative or e-mail This email address is being protected from spambots. You need JavaScript enabled to view it.. To learn more or register for SNEC, please visit the event web site at - http://www.snec.org.cn/HomePage.aspx?lang=en.

Our collective cleantech banking team has been involved in ~170 cleantech transactions over the past decade with a total transaction value of over $16B. (Source – ROTH Capital – 05/17/2019)

ROTH is a founding member of Sustain SoCal (formerly Sustain OC), a trade association with its roots in cleantech economic growth that accelerates sustainability in Southern California through innovation, collaboration and education. ROTH is also a member of Solar Energy Industries Association (SEIA).

Event sponsors include Business Wire and The Blueshirt Group Asia.

List of participating companies as of this release (As of 05/23/2019 – subject to change):

Company Name

Arctech Solar PRIVATE
Asia Clean Capital PRIVATE
Canadian Solar Inc. CSIQ
Daqo New Energy Corp. DQ
GameChange Solar LP* PRIVATE
Huawei Technologies Co. Ltd. PRIVATE
Human Horizons PRIVATE
JinkoSolar Holding Co., Ltd. JKS
Jolywood* SZ: 300393
Longi Green Energy Technology SSE: 601012
Meyer Burger* MBTN
Nio Inc. NIO
PV Infolink PRIVATE
Singapore Solar Exchange PRIVATE
TBEA* SH: 600089
Tianjin Zhonghuan* SZ: 002129
Tongwei Co., Ltd SH: 600438
WM Motor PRIVATE
Wuxi Lead Intelligent Equipment SZSE: 300450
Xinyi Glass HK: 00968
 

*Invited as of 05/23/2019

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.

Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains regional offices throughout the U.S. For more information on ROTH, please visit www.roth.com.

Read more: CORRECTING and REPLACING 6th Annual ROTH China...

SINGAPORE, May 23, 2019 /PRNewswire/ -- Kimberly-Clark today switched on one of Singapore's largest solar energy installations at its manufacturing facility in Tuas, which produces Huggies diapers and Huggies baby wipes. The 7,730 photovoltaic panels mounted on its roof will generate 3.5 Gigawatt hours of clean energy, enough to power up a thousand 3-bedroom HDB flats for a year.

Kimberly-Clark switched on one of Singapore’s largest solar energy installations at its manufacturing facility in Tuas, which produces Huggies diapers and Huggies baby wipes. The 7,730 photovoltaic panels mounted on its roof will generate 3.5 Gigawatt hours of clean energy.
Kimberly-Clark switched on one of Singapore’s largest solar energy installations at its manufacturing facility in Tuas, which produces Huggies diapers and Huggies baby wipes. The 7,730 photovoltaic panels mounted on its roof will generate 3.5 Gigawatt hours of clean energy.

With this investment, renewable energy will now replace 15% of conventional energy use at the plant, reducing greenhouse gas emissions (GHGs) by approximately 1,600 metric tons per year. This is equivalent to removing nearly 350 passenger cars from roads annually.

Kimberly-Clark's Tuas plant has a long track record of reducing its environmental footprint. In 2016, it launched an in-house wastewater treatment plant that recycles 75% of the water used in its wet wipes production.

Since 2017, it has partnered with Ngee Ann polytechnic researchers to find utility for material waste generated during its production process, as part of its broader efforts to re-use or recycle 100% of its waste.

At a ceremony held to inaugurate its solar roof, Achal Agarwal, President, Kimberly-Clark Asia Pacific, said, "Our manufacturing operations in Singapore have long been recognized as a leader in environmental protection. Switching on this solar roof marks a new milestone in our sustainability journey and accelerates our progress towards our goal of achieving a 20% reduction in GHG emissions globally, by 2022."

Through continued investments in climate and energy programs at its operations around the world, Kimberly-Clark has embarked on a long-term effort to minimize climate change impact from its operations and at the same time transform its financial performance.

Mr. Masagos Zulkifli, Singapore's Minister for the Environment and Water Resources, was the guest of honour at the inauguration. He said, "I am glad to see enterprises such as Kimberly-Clark Corporation step up efforts to adopt renewable energy. Sustainable development is not just central to the mitigation of climate change and protection of the environment. When thoughtfully incorporated, it can benefit business operations and reduce costs in the long run."

The solar roof panels were installed in partnership with Singapore-based solar energy provider Sunseap, which has played an instrumental role in the development of many grid-connected PV systems, pioneering the solar energy movement in Singapore.

"We are pleased to work with Kimberly-Clark in their efforts to go green. As the leading integrated clean energy solutions provider in Singapore, we encourage all companies to look for ways to be environmentally friendly in their business. There are various measures companies can take to reduce their carbon footprint including tapping renewable energy for their operations and going paperless in their day-to-day work," said Frank Phuan, CEO and Executive Director, Sunseap Group.

About Kimberly-Clark
Kimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them. Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Neve, Plenitud, Viva and WypAll, hold the No. 1 or No. 2 share position in 80 countries. We use sustainable practices that support a healthy planet, build stronger communities, and ensure our business thrives for decades to come. To keep up with the latest news and to learn more about the company's 147-year history of innovation, visit kimberly-clark.com or follow us on Facebook or Twitter.

[KMB-C]

SOURCE Kimberly-Clark

Related Links

http://www.kimberly-clark.com

Read more: Kimberly-Clark switches on one of Singapore's...

More Articles ...

Subcategories

Advertisement

Translator

Advertisement
Advertisement

SolarQuarter Tweets

Follow Us For Latest Tweets

SolarQuarter Gujarat Largest Rooftop Solar Event is Back in Ahmedabad - https://t.co/hvfKU8siIr
Monday, 20 May 2019 06:35
SolarQuarter How did India solar tenders perform in 2018-19? Here's a snapshot! solarenergy solarnews energy… https://t.co/rEDOp84n27
Wednesday, 15 May 2019 20:12
SolarQuarter Who was awarded the maximum tenders in India in 2018-19? Here's a glimpse @SolarQuarter SolarQuarter… https://t.co/jUdsZVJ5VU
Wednesday, 15 May 2019 00:29

Advertisement